Ambetter (Centene) GLP-1 Coverage & Prior Authorization Guide: Why Weight-Loss GLP-1s Are Excluded (2026)

Ambetter (Centene's ACA Marketplace brand) and Centene/Wellcare plans do not cover GLP-1 medications for chronic weight management. Wegovy, Zepbound, and Saxenda for obesity are an explicit benefit exclusion under Centene's own clinical policy. GLP-1s ARE covered — with prior authorization only — for other FDA-approved indications: type 2 diabetes (Ozempic, Mounjaro), semaglutide for cardiovascular risk reduction, and Wegovy for MASH, with state-specific variation. This guide quotes Centene's policy verbatim and maps the narrow non-obesity paths that actually get approved.

Bottom line: Ambetter excludes weight-loss GLP-1s

• Centene Clinical Policy CP.PMN.295 (Semaglutide/Wegovy), effective 06/01/24, for Marketplace and Medicaid lines: weight management is a benefit exclusion and “will not be authorized.”
• The same policy DOES allow Wegovy PA for cardiovascular event prevention (established CVD + BMI ≥ 27 + age ≥ 18) and for MASH (F2-F3 fibrosis) — coverage hinges on a non-obesity FDA indication, not weight loss.
• Ambetter provider guidance lists Wegovy (obesity) and Saxenda (obesity) both as “Non-covered benefit.”
• Ambetter Arkansas member notice (Nov 21, 2025): “Ambetter does not currently cover GLP-1s when prescribed solely for weight management”; members may owe the full out-of-pocket cost.
• For concurrent type 2 diabetes, Wegovy PA requires step therapy through ≥ 3 consecutive months each of Ozempic/Rybelsus, Trulicity, and generic liraglutide (Victoza) unless contraindicated — confirming diabetes GLP-1s are on formulary.
• Wellcare (Centene Medicare Part D) follows the federal Part D statutory weight-loss exclusion: GLP-1s covered only for non-weight-loss FDA uses (diabetes, CV risk reduction, OSA).
• Ambetter is state-specific (separate formularies per state subsidiary, e.g. Health Net CA, Sunshine FL); obesity-drug availability on ACA plans is plan/state-dependent, and a handful of states mandate obesity-drug coverage on Marketplace plans.

What Centene's policy says

“Use of Wegovy for the treatment of weight management is a benefit exclusion and will not be authorized.”

— Centene Clinical Policy CP.PMN.295 Semaglutide (Wegovy), Sec. III.B.

“Ambetter does not currently cover GLP-1s when prescribed solely for weight management.”

— Ambetter Arkansas member news (Nov 21, 2025).

“GLP-1s may be covered for FDA-approved uses other than weight loss, such as Type 2 diabetes, cardiovascular risk reduction or obstructive sleep apnea.”

— Wellcare: Does Medicare Cover Weight-Loss Drugs? (2026).

When GLP-1s ARE covered (non-obesity indications)

• No PA path exists for weight management itself (hard benefit exclusion). The criteria below apply to the COVERED non-obesity indications.
• Cardiovascular event prevention (Wegovy): established CVD (prior MI, stroke, or symptomatic PAD); age ≥ 18; BMI ≥ 27; prescriber attestation of CV standard-of-care. Initial approval 6 months.
• Concurrent type 2 diabetes: documented ≥ 3 consecutive months each of Ozempic/Rybelsus, Trulicity, and generic liraglutide unless contraindicated (GI intolerance alone not accepted). Illinois waived step therapy 1/1/2026 per HB 5395.
• MASH (Wegovy): MASH diagnosis, prescribed by/with a hepatologist or gastroenterologist, age ≥ 18, F2-F3 fibrosis confirmed.
• Continued therapy for the CV indication requires ≥ 5% baseline weight loss at first renewal with current-weight documentation.

How to appeal an Ambetter denial

• Marketplace members may file an internal appeal within 180 calendar days of a PA or medical-necessity denial.
• Ambetter must resolve standard appeals within 30 calendar days (faster if the case is expedited or urgent).
• After the internal appeal, members may request an independent external review.
• Exact steps, forms, and deadlines are in each state plan's Evidence of Coverage; provider appeal forms live on the state-specific Ambetter “Grievance and Appeals” pages.

Formularies, tiers, and state obesity-coverage mandates vary by state subsidiary — confirm your state plan's drug list. Zepbound's weight-management exclusion is inferred from the identical anti-obesity treatment of Wegovy/Saxenda; verify Centene's tirzepatide policy before a Zepbound-specific claim. The July 2026 Medicare GLP-1 Bridge is a CMS program, not an Ambetter/Wellcare benefit. This article is informational and does not constitute medical or legal advice.

Further reading

• Cheapest GLP-1 without insurance: buyer's guide
• Best semaglutide providers